GeneSight
GeneSight is a pharmacogenomic testing brand owned by Myriad Genetics that provides genetic analysis to personalize medication selection for patients with depression, anxiety, ADHD, and other psychiatric conditions, serving a network of 25,000+ healthcare providers in the United States.
- Company typePrivate
- Founded2006
- HeadquartersMason, United States
- Headcount251–500
- GTM typeB2B
- OfferingServices
What GeneSight does
GeneSight is a pharmacogenomic (PGx) testing brand operated by Myriad Genetics, Inc. (NASDAQ: MYGN) through its subsidiary Assurex Health, Inc. (dba Myriad Neuroscience), headquartered in Mason, Ohio. The company provides genetic testing services that analyze how patients' genetic variations may affect their responses to medications commonly prescribed for depression, anxiety, ADHD, and other psychiatric conditions. Its core offering, the GeneSight Psychotropic test, uses a proprietary weighted multi-gene algorithm that evaluates 14 genes (9 pharmacokinetic and 5 pharmacodynamic) to classify over 60 mental health medications into three categories indicating the likelihood of efficacy and risk of side effects. The test must be ordered by a registered healthcare provider, with results delivered via a secure clinician portal (myGeneSight.com) within approximately 3 days of sample receipt.
The company's underlying technology integrates results from published clinical studies, pharmacology references, and FDA labels into a proprietary classification system. Tests are processed in a CLIA- and CAP-accredited laboratory, and the platform has been validated through 7 clinical studies published in peer-reviewed journals, including the PRIME Care study, the largest pharmacogenomic randomized controlled trial ever conducted in mental health, sponsored by the U.S. Department of Veterans Affairs. The GeneSight MTHFR test extends the offering to assess folate metabolism, and the GeneSight at Home collection kit enables remote sample collection.
GeneSight generates revenue by performing laboratory testing services and billing insurance providers (Medicare, Medicaid, and commercial plans) directly. The company has established a self-pay rate of $330, with 98% of patients paying $330 or less out of pocket. Its go-to-market combines enterprise field sales to register and support healthcare providers with patient-facing demand generation through educational content, testimonials, and an annual GeneSight Mental Health Monitor survey. The provider network includes 25,000+ clinicians, and over 3 million people have taken the test cumulatively.
GeneSight firmographics
Firmographics- Name
- GeneSight
- Legal name
- Myriad Genetics, Inc.
- Website
- https://genesight.com
- Company type
- Private
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- GeneSight is a pharmacogenomic testing brand owned by Myriad Genetics that provides genetic analysis to personalize medication selection for patients with depression, anxiety, ADHD, and other psychiatric conditions, serving a network of 25,000+ healthcare providers in the United States.
- Ownership category
- akta.pro rank
GeneSight industry classification
Industry- Product category
- Pharmacogenomic Testing Services
- NAICS
- Medical Laboratories (621511)
- akta.pro primary industry
- Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)
- akta.pro secondary industry
- Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)
Keywords
Where GeneSight is headquartered
LocationHeadquarters
- HQ city
- Mason
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
GeneSight business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain
Revenue model
- Laboratory Testing Services: GeneSight generates revenue by performing pharmacogenomic testing services. The company bills insurance (Medicare, Medicaid, commercial) directly for the test. Patients pay out-of-pocket only if insurance doesn't cover or denies coverage, with 98% of patients paying $330 or less. Financial assistance is available for eligible patients.
- Insurance Billing: The company bills insurance companies directly. Medicare (Part B) and Medicare Advantage typically cover the full cost ($0 patient responsibility). Commercial insurance coverage varies. The company reviews patient insurance benefits before processing to estimate out-of-pocket costs.
- Self-Pay Option: Uninsured patients or those whose insurance doesn't cover the test can opt for the reduced self-pay rate of $330. Payment plans are available for costs of $100 or more, spread over up to 12 months interest-free.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | Medicare/Medicaid Coverage - $0 out of pocket |
| One time/ perpetual license | Pay-as-you-go | Commercial Insurance - $330 or less |
| One time/ perpetual license | Pay-as-you-go | Self-Pay/Uninsured - $330 |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels9 records
GeneSight product offering
Product offeringCore offering
GeneSight is a pharmacogenomic testing service that analyzes clinically important genetic variations in patient DNA to help healthcare providers predict how patients with depression, anxiety, ADHD, and other psychiatric conditions may metabolize or respond to mental health medications. The test must be ordered by a registered clinician and is processed at the company's own CLIA and CAP accredited laboratory, with results typically delivered in approximately 3 days.
Product overview
GeneSight is a pharmacogenomic testing platform offered by Myriad Genetics that provides genetic insights to help personalize mental health medication treatment. The core offering is the GeneSight Psychotropic test, which analyzes how a patient's genes may affect their outcomes with medications for depression, anxiety, ADHD, and other psychiatric conditions. The platform also includes the GeneSight MTHFR test as an add-on to assess folate metabolism. Sample collection is available either in-office via simple cheek swab or through the GeneSight at Home collection kit for remote patients. Results are delivered to clinicians through a secure portal within approximately 3 days of sample receipt.
Differentiator
Problem solved
Functional benefit
Brands
- GeneSight Psychotropic: Pharmacogenomic test analyzing how genetic variations may affect medication outcomes for depression, anxiety, ADHD, and other psychiatric conditions.
- GeneSight MTHFR
- GeneSight at Home
- Myriad Neuroscience
Products and services
- GeneSight Psychotropic
Quantifiable outcome
- Patients who received GeneSight testing saved over $1,000 in total annual medication costs compared to traditional approaches
- +5 more outcomes
Companies that use GeneSight
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles2 records
GeneSight technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
GeneSight partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Iraq and Afghanistan Veterans of America (IAVA)coreIAVA partnered with Myriad Genetics to raise awareness about genetic testing and mental health treatment options available to veterans. The partnership included a live event featuring clinical experts sharing new research about treatment for veterans with mental health conditions. IAVA is a leading veterans organization working to connect, represent, and counsel post-9/11 veterans.
Scale indicators12 records
Recent moves6 records
Expansion highlights5 records
GeneSight competitors and assessment
Company assessmentBroad incumbents
- Quest Diagnostics: Quest Diagnostics is a large national clinical laboratory that offers pharmacogenomic and mental-health-adjacent genetic tests through its broad test menu. It competes with GeneSight at the payer and provider level and shares the CLIA-certified lab model.
- Myriad Genetics: Myriad Genetics is GeneSight's publicly-traded parent company (NASDAQ: MYGN) and a broad incumbent in molecular diagnostics, with overlapping genetic testing infrastructure and other franchises (e.g., oncology, reproductive health) sharing the same lab, billing, and commercial platforms.
- Laboratory Corporation of America (Labcorp): Labcorp is a large national clinical laboratory offering a wide range of PGx and specialty genetic tests, including mental-health-relevant panels. Its scale, payer contracts, and clinician relationships make it an indirect but powerful competitor to GeneSight's specialty PGx franchise.
Direct peers
- PreventionGenetics (part of Exact Sciences): PreventionGenetics is a CLIA-certified clinical DNA testing laboratory offering a broad menu of genetic tests, including pharmacogenomic panels. It competes with GeneSight in the clinical genetic testing market serving healthcare providers and patients.
- Genomind: Genomind is the closest direct competitor to GeneSight in psychiatric pharmacogenomic testing, offering the Genecept Assay and related PGx panels targeting mental-health prescribers with a similar clinician-gated, evidence-led go-to-market model.
Emerging players
- 23andMe: 23andMe is a consumer-facing genetic testing company that has expanded into health-related genetic reports, including pharmacogenomic traits. Its direct-to-consumer model and large customer database make it an adjacent peer for patient-initiated demand dynamics.
- Tempus Labs: Tempus is an emerging precision-medicine player applying AI-driven analytics to molecular and clinical data, including pharmacogenomics. While primarily oncology-focused, its data-platform approach and provider integration overlap with GeneSight's evidence-driven PGx model.
- Color Health: Color Health offers population-scale genetic testing with a CLIA-certified lab and an enterprise/employer distribution model. Its infrastructure and clinical-grade genetic testing overlap with GeneSight, and its employer-driven channel represents a parallel go-to-market approach.
- Castle Biosciences: Castle Biosciences is a molecular diagnostics company that develops and commercializes genomic tests to aid treatment decisions, primarily in oncology and dermatology. It shares GeneSight's evidence-based, clinician-gated, specialty-testing commercial model.
- Coriell Life Sciences: Coriell Life Sciences offers pharmacogenomic interpretation and clinical decision support tools used by health systems and employers. It overlaps with GeneSight in PGx-focused enterprise and health-plan channels, and competes for prescriber mindshare in medication-guided treatment.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
GeneSight social profiles
Digital presenceGeneSight financial estimates
Financial estimateRevenue estimate
Valuation estimate
GeneSight leadership team
Management profileNumber of profiles
Profiles5 records
GeneSight funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
GeneSight M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about GeneSight
What does GeneSight do?
GeneSight is a pharmacogenomic testing service that analyzes clinically important genetic variations in patient DNA to help healthcare providers predict how patients with depression, anxiety, ADHD, and other psychiatric conditions may metabolize or respond to mental health medications. The test must be ordered by a registered clinician and is processed at the company's own CLIA and CAP accredited laboratory, with results typically delivered in approximately 3 days.
Is GeneSight a public or private company?
GeneSight is a private company. It is classified as public and is currently operating.
When was GeneSight founded?
GeneSight was founded in 2006. It employs 251 to 500 people.
Where is GeneSight based?
GeneSight is headquartered in Mason, United States, in the North America region.
How does GeneSight make money?
Three revenue lines are on record. Laboratory Testing Services are the primary driver. The others are insurance Billing and self-Pay Option.
Who are GeneSight's main competitors?
Broad incumbents on record are Quest Diagnostics, Myriad Genetics and Laboratory Corporation of America (Labcorp). Direct peers are PreventionGenetics (part of Exact Sciences) and Genomind. Emerging players are 23andMe, Tempus Labs, Color Health, Castle Biosciences and Coriell Life Sciences.
Does GeneSight have an API?
No public API is recorded for GeneSight.
What industry is GeneSight in?
GeneSight's product category is Pharmacogenomic Testing Services. Its primary akta.pro industry code is HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics), with a secondary code of HLAFAMAE, Molecular Diagnostics & Genomics Laboratories. Its NAICS code is 621511.